JT
RAPP

Jupiter Topco’s Rapport Therapeutics RAPP Stock Holding History

Jupiter Topco’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$574K Buy
+13,800
New +$507K ﹤0.01% 2034

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Jupiter Topco's RAPP Position: Q2 2026 in Review

Jupiter Topco opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 13,800 shares worth $574K. The stake represents ﹤0.01% of the portfolio and ranks #2034 among its holdings.

146 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Jupiter Topco held 13,800 shares of Rapport Therapeutics worth $574K as of Q2 2026.
  • Rapport Therapeutics was a new Jupiter Topco position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #2034 holding.
  • 146 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.